New drug duo targets tough lung cancer mutation
NCT ID NCT07227025
Summary
This study is testing a new combination of two drugs, amivantamab and olomorasib, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The main goals are to find the safest and most effective dose of the drug pair and to see how well it works to slow or stop the growth of tumors. The study is for people whose cancer has spread and has stopped responding to standard treatments like chemotherapy and immunotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
New York University Langone Medical Center
RECRUITINGNew York, New York, 10016, United States
-
Princess Margaret Hospital
RECRUITINGToronto, Ontario, M5G 2M9, Canada
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Shanghai East Hospital
RECRUITINGShanghai, 310000, China
-
Virginia Cancer Specialists
RECRUITINGFairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.